Jean Jacques Bienaime
Director · 7 filings · Latest: Jun 3, 2026
Ascendis Pharma A/S
INCYTE CORP
Immunome Inc.
Keros Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
KROS | Jean Jacques Bienaime | Director | Jun 3, 2026 | Grant/Award | $0.00 | 7,142 | — | 16,592 | |
ASND | Jean Jacques Bienaime | Director | May 29, 2026 | Purchase | $223.12 | 500 | $111.6K | 900 | |
INCY | Jean Jacques Bienaime | Director | May 26, 2026 | Tax Withholding | $97.10 | 13,059 | $1.3M | 22,782 | |
INCY | Jean Jacques Bienaime | Director | May 26, 2026 | Option Exercise | $84.53 | 15,000 | $1.3M | 35,841 | |
ASND | Jean Jacques Bienaime | Director | May 26, 2026 | Purchase | $237.80 | 400 | $95.1K | 400 | |
KROS | Jean Jacques Bienaime | Director | May 15, 2026 | Purchase | $10.58 | 1,000 | $10.6K | 9,450 | |
IMNM | Jean Jacques Bienaime | Director | May 15, 2026 | Purchase | $20.70 | 5,000 | $103.5K | 43,415 | |
KROS | Jean Jacques Bienaime | Director | Apr 15, 2026 | Purchase | $11.70 | 1,000 | $11.7K | 8,450 |